Familial and acquired hemophagocytic lymphohistiocytosis

By G. Janka. European Journal of Pediatrics, 2006

746 citations recorded by the source corpus.

Subfields: Hematology, Immunology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/206b766d19529413664e8468baeda43be5e413a8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rose‐John
2. C. June
3. C. A. Dinarello
4. J. Kochenderfer

In Immunology

1. C. June
2. S. Rose‐John
3. Miriam Merad
4. B. Rollins
5. C. A. Dinarello
6. J. Kochenderfer

Citations in the corpus

• Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). (2009, background): “Scavenger macrophage: activated macrophage that scavenges haptoglobinhemoglobin complexes via the CD163 receptor, phagocytoses erythrocytes, and secretes proinflammatory cytokines and ferritin mutations in several genes important to cytotoxic T cell and natural killer (NK) cell function (36, 37).”
• Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. (2017, neutral): “Dead at 1 y (% of all) 67 (18) 23 (14) 44 (22) 41 (17) 27 (21) 56 (24)”
• Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. (2016, background): “Hemophagocytic lymphohistiocytosis (HLH) is a rare, often-fatal syndrome of intense immune activation characterized by fever, cytopenias, hepatosplenomegaly, and hyperferritinemia.(81) Although HLH has various underlying causes, all subtypes of HLH are related to immune dysregulation that leads to h”
• Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. (2011, background): “Patient characteristics in history, clinical findings, and laboratory parameters before start of therapy in all patients, as well as in 4 different subgroups: (1) patients with an affected sibling; (2) patients who died within the first 8 weeks of therapy; (3) patients who underwent HSCT; and (4) pa”
• Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia (2016, methodology): “Fibrinogen at <150 mg/dL is used in the diagnostic criteria for HLH as it is a sensitive marker of the syndrome (10).”